Daewoong Innovates Biopharmaceutical Production with Digital Twin Technology

Selected as a National Project by the Ministry of Trade, Industry and Energy

Daewoong announced on July 28 that its project, "Development of Next-Generation Biopharmaceutical Manufacturing Process Technology Based on Digital Twin," has been finally selected as a national research project for the "2025 First Biohealth R&D Project," which is supervised by the Ministry of Trade, Industry and Energy.

Daewoong Pharmaceutical researchers conducting research. Daewoong

Digital twin is a next-generation manufacturing technology that recreates the actual biopharmaceutical production process in a virtual environment, continuously monitoring and optimizing the process status through real-time data collection and simulation. This enables the prediction of potential issues in advance and allows for swift responses during the process.

In particular, unlike the traditional design of experiment (DoE) approach, which requires repeated experiments by changing various conditions such as temperature, time, and humidity one by one, digital twin technology allows for the simulation of various process conditions to rapidly and in real time derive optimal process parameters. This increases flexibility in process development, improves productivity and quality, and contributes to reducing both development time and costs. Therefore, in biopharmaceutical processes that are sensitive to change and highly complex, digital twin is emerging as a core technology that enhances both the predictability and precision of process control.

This project aims to actively apply digital twin, which is recognized as a future core technology, to biopharmaceutical production processes. In particular, it is expected to strengthen digital automation, unmanned operations, and data-driven control capabilities.

Through this national project, Daewoong plans to establish an "integrated digital twin system" that encompasses the entire process from cell culture to purification, which are key steps in biopharmaceutical manufacturing.

Daewoong has already introduced and is operating digital automation solutions at the Daewoong Pharmaceutical Osong Smart Factory in Chungbuk. Through this project, the company plans to accumulate research results and simulation data based on digital twin processes and apply them to actual biopharmaceutical manufacturing, thereby further strengthening its next-generation manufacturing capabilities.

Yoo Jimin, head of Daewoong Bio R&D Center, stated, "This national project is highly significant in that it applies digital twin-based process technology, which is recognized as a future-leading technology, to actual biopharmaceutical manufacturing processes. Not only can we dramatically reduce R&D costs and time and secure quality stability, but we will also lead the domestic bioprocess industry through advanced technology and precise data-driven prediction."